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Abstract 
Background: Hypertension is a multifactorial disease caused by the interaction between genetic and environmental 
factors. Mutations in the methylenetetrahydrofolate reductase gene (MTHFR) have been known to be associated with 
the risk of cardiovascular disease as well as hypertension. This case–control study was conducted out to measure the 
association of the polymorphism C677T of MTHFR with the risk of hypertension.
Methods: Polymerase chain reaction followed by restriction fragment analysis length was used to identify MTHFR 
C677T genotypes in patients 101 patients and 102 age and sex matched healthy controls. Odds ratio with 95 % confi-
dence interval was used to assess the risk of association.
Results: The distribution of demographic and clinical features of patients showed no particular trend (p > 0.05). 
However, the frequency of homozygous 677T allele was higher in patients with a family history of heart disease (30.4 
vs. 9 %, p = 0.031). Interestingly, the mutant 677TT genotype was significantly associated with the susceptibility 
of hypertension when compared to the wild type 677CC genotype (OR 5.4, CI 1.4–19.8, p = 0.008). In addition, the 
recessive model 677TT vs. 677CC/CT was found to be associated with the risk of hypertension (OR 5.3, CI 1.5–19.1, 
p = 0.005). However, the dominant model was not associated with the risk of hypertension in our cohort (OR 1.3, CI 
0.7–2.2, p = 0.4).
Conclusions: Based on our findings, the homozygous mutant for 677TT of MTHFR gene is associated with the risk 
of hypertension in our population. Further studies with larger sample sizes are needed to confirm the results of this 
study.
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Background
Hypertension is a major public health concern in the 
world. It is found to be the main factor in the occur-
rence of myocardial infarction, stroke, cardiac and renal 
failure and later lesions of the retina of the eyes [1, 2]. 
In Morocco, the prevalence of hypertension in men and 
women is 30.2 and 37  %, respectively, with an overall 
prevalence of 33.6 % [3, 4]. The etiology of hypertension, 
like most of multifactorial diseases is not known. How-
ever, the pathogenesis of hypertension can be explained 
by the interaction between many factors such as sodium 
intake, overweight, alcohol, smoke and the genetic back-
ground of subjects [5, 6]. Many authors have shown the 
fundamental role of genetic factors not only in the devel-
opment of hypertension, but also in the individualization 
of treatment [7, 8]. Methylenetetrahydrofolate reductase 
gene (MTHFR) is particularly involved in the metabolism 
of homocysteine and folate by catalyzing the 5, 10-meth-
ylenetetrahydrofolate into 5-methylenetetrahydrofolate. 
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The MTHFR gene has been mapped to chromosome 
1p36.3 and encodes an enzyme composed of 656 amino 
acids [9]. It was reported that, conditions such as hyper-
homocysteinemia and homocystinuria are associated 
with mutations in the MTHFR gene. The single nucleo-
tide polymorphism 677C  >  T (Alanine222Valine) of 
MTHFR reduces the enzymatic activity [10]. As a result, 
individuals this mutation are exposed to a high level of 
homocysteine in plasma and are more likely to develop 
cardiovascular disease, due to the absence of conversion 
of homocysteine to methionine by 5-methylenetetrahy-
drofolate [11, 12]. It has been shown that the MTHFR 
enzyme activity decrease is attributable to the loss of 
cofactor of Riboflavin. Thus, the supplementation of 
this latter, contributes to the reduction of hyperhomo-
cysteinemia in hypertensive patients with the variant of 
MTHFR [13–15]. A recent study showed that supple-
mentation with Riboflavin in hypertensive patients carry-
ing the homozygous genotype mutant 677TT of MTHFR, 
without other cardiovascular diseases, has considerably 
improved the value of systolic blood pressure, paving 
the way for personalized medicine [16]. It is worth not-
ing, that numerous studies investigated the relationship 
between the C677T polymorphism of MTHFR and many 
diseases, including breast cancer [17, 18], colorectal can-
cer [19], ischemic stroke [20, 21], inflammatory bowel 
disease [22] and hypertension [7, 23, 24]. In the light 
of the limited data on the variants of the MTHFR and 
hypertension in our population, and the role of vitamin 
B2 in the improvement of blood pressure in hyperten-
sive patients with a mutant variant of the MTHFR gene, 
this case–control study was carried out to investigate the 
association of 677C > T polymorphism of MTHFR with 




The study included 101 outpatients (77 females and 24 
males) with a mean age of 61.6 ± 9 (range 40–87 years) 
and 102 age and sex matched unrelated healthy con-
trol subjects with a mean age of 59.24  ±  10.7 (range 
40–87 years). Patients have been confirmed with hyper-
tension by cardiologists according to the criteria of 
International Society of Hypertension [systolic blood 
pressure (SBP) ≥ 140 mmHg or diastolic blood pressure 
(DBP)  ≥  90  mmHg] [25]. Patients were recruited from 
the department of cardiology of the Ibn Rochd University 
Hospital in Casablanca, Morocco from 2011 to 2013. The 
control group was normotensive after medical examina-
tion (SBP < 140 mmHg or DBP < 90 mmHg) without any 
family history of cardiovascular, diabetes and thyroid dis-
eases and was recruited at the laboratory of genetic and 
molecular diseases, Faculty of Medicine, the Hassan II 
University in Casablanca. The control subjects were com-
posed of employees working at the faculty of medicine. 
The study received the approval from the local Ethics 
Committee and all participants accepted and signed the 
informed consent. Five milliliters of venous blood were 
collected from each participant in an EDTA tube for the 
genotyping of the MTHFR gene.
Identification of MTHFR C677T polymorphism
Genomic DNA was extracted from white blood cells by 
using the salting-out method described previously by 
Miller et  al. [26]. Polymerase chain reaction followed 
by the restriction fragment length polymorphism was 
used to genotype the C677T polymorphism of MTHFR. 
The conditions of amplification and digestion have been 
well documented previously in our laboratory [19]. The 
digested PCR products after separation on a 3 % agarose 
gel, stained with ethidium bromide, showed one band 
of 198  bp corresponding to the wild type homozygous 
(CC), three bands of 198, 175 and 23 bp for the heterozy-
gous (CT), two bands of 175 and 23 bp for the mutated 
homozygous (TT).
Statistical analysis
The statistical package for the social sciences SPSS ver-
sion 16 (SPSS Inc., Chicago, IL, USA) was used to 
perform all statistical analyses. The difference in the dis-
tribution of demographic data, clinical characteristics 
of patients as well as their family history and MTHFR 
C677T genotypes were conducted by Fisher’s exact test. 
Hardy–Weinberg equilibrium in the cases and controls 
was evaluated by Chi square test. The estimation of the 
association between MTHFR C677T profiles and the risk 
of hypertension was evaluated by Fisher’s exact test fol-
lowed by the calculation of an odds ratio (OR) with 95 % 
confidence interval. Statistical tests were considered sig-
nificant when the p value was less than 0.05.
Results
The present case–control study assessed the distribution 
of the C677T polymorphism of MTHFR in 101 patients 
with hypertension and 102 controls without any history 
of hypertension. The frequencies of alleles and geno-
types of C677T in patients and controls did not deviate 
from Hardy–Weinberg equilibrium (p > 0.05). As shown 
in Table  1, the distribution of CC, CT and TT geno-
types in patients with respect to demographic data and 
clinical features (gender, age, body mass index, diabetes, 
dyslipidemia, risk stage, smoking habit) did not show a 
particular trend (p > 0.05). The stratification of patients 
according to their family history showed that carriers of 
mutated homozygous TT with a family history of heart 
Page 3 of 5Nassereddine et al. BMC Res Notes  (2015) 8:775 
disease were significantly associated with the risk of 
hypertension (30.4 vs. 9 %, p = 0.031). The distribution 
of other family histories such as hypertension, stroke, 
heart disease, diabetes, kidney disease and dyslipidemia 
were comparable between the different genotypes of 
MTHFR C677T with p > 0.05 (Table 2). In Table 3, the 
frequency of the homozygous wild type CC was higher 
in the control group than in patients (52.9 vs. 46.5  %). 
However, the frequency of the mutant TT was higher in 
cases than controls (13.9 vs. 2.9 %) and the TT genotype 
was found to be statistically associated with the risk of 
hypertension when compared with carriers of homozy-
gous wild type CC (OR 5.4, CI 1.4–19.8, p = 0.008). Fur-
thermore, the comparison of TT to CC/CT carriers in 
the recessive model showed the same trends with a risk 
of 5.3 (p = 0.005). However, the dominant model did not 
show any particular effect concerning the risk of hyper-
tension. The frequency of mutant 677T allele was higher 
in cases compared to controls (34 vs. 25  %), but not 
significantly.
Discussion
Hypertension is a multifactorial disease that involves 
both genetic and environmental factors and it is known 
to be a common risk factor for kidney and heart com-
plications. Hereditary genetic differences in MTHFR 
gene and the risk of hypertension have been discussed 
by many authors with conflicting results. In the current 
Table 1 Distribution of  clinical and  demographic fea-
tures of the patients, according to the different genotypes 
of MTHFR C677T
FH family history, CC homozygous wild type, CT heterozygous, TT homozygous 
variant
Parameters C677T N (%) χ2 p
CC CT TT
Gender
 Female 35 (45.5) 30 (39) 12 (15.5) 0.8 0.6
 Male 12 (50) 10 (41.7) 2 (8.3)
Age (years)
 40–60 27 (49.1) 20 (36.4) 8 (14.5) 0.5 0.7
 61–87 20 (43.5) 20 (43.5) 6 (13)
BMI (kg/m2)
 18–24 14 (48.3) 9 (31) 6 (20.7) 5.2 0.3
 25–30 19 (43.2) 22 (50) 3 (6.8)
 >30 14 (50) 9 (32.1) 5 (17.9)
Diabetes
 Yes 14 (45.2) 12 (38.7) 5 (16.1) 0.2 0.9
 No 33 (47.1) 28 (40) 9 (12.9)
Dyslipidemia
 Yes 15 (41.7) 14 (38.9) 7 (19.4) 0.5 0.5
 No 32 (49.2) 26 (40) 7 (10.8)
Stage of risk
 Low 9 (34.6) 12 (46.2) 5 (19.2) 6.35 0.2
 Medium 24 (58.5) 11 (26.8) 6 (14.6)
 High 14 (41.2) 17 (50) 3 (8.8)
Smoking habit
 Yes 6 (46.2) 5 (38.5) 2 (15.4) 0.03 1
 No 41 (46.6) 35 (39.8) 12 (13.6)
Table 2 Distribution of  MTHFR genotype according 
to patient’s family history
CC homozygous wild type, CT heterozygous, TT homozygous variant
Family history C677T N (%) χ2 p
CC CT TT
Hypertension
 Yes 29 (50) 23 (39.7) 6 (10.3) 1.6 0.5
 No 18 (41.9) 17 (39.7) 8 (18.6)
Heart disease
 Yes 8 (34.8) 8 (34.8) 7 (30.4) 6.9 0.031
 No 39 (50) 32 (41) 7 (9)
Stroke
 Yes 7 (43.8) 7 (43.8) 2 (12.5) 0.14 0.9
 No 40 (47.1) 33 (38.8) 12 (14.1)
Diabetes
 Yes 18 (40) 20 (44.4) 7 (15.6) 1.4 0.5
 No 29 (51.8) 20 (35.7) 7 (12.5)
Kidney disease
 Yes 1 (12.5) 6 (75) 1 (12.5) 4.9 0.08
 No 46 (49.5) 34 (36.6) 13 (14)
Dyslipidemia
 Yes 12 (48) 8 (32) 5 (20) 1.4 0.5
 No 35 (46.1) 32 (42.1) 9 (11.8)
Table 3 Distribution of  genotypes and  alleles of  MTHFR 
in patients and controls
HWE Hardy–Weinberg Equilibrium, N number
a Recessive model
b Dominant model
Patients N (%) Control N (%) OR (95 % CI) p
C677T
 CC 47 (46.5) 54 (52.9) Ref.
 CT 40 (39.6) 45 (44.2) 1 (0.6–1.8) 1
 TT 14 (13.9) 3 (2.9) 5.4 (1.4–19.8) 0.008
 CC/CTa 87 (86) 99 (97) Ref.
 TT 14 (14) 3 (3) 5.3 (1.5–19.1) 0.005
 CCb 47 (46) 54 (53) Ref.
 CT/TT 54 (54) 48 (47) 1.3 (0.7–2.2) 0.4
 C 134 (66) 153 (75) Ref.
 T 68 (34) 51 (25) 1.5 (1–2.3) 0.06
 HWE: p value 0.27 0.11
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study, the genotype correlation of patients with regard to 
parameters such as gender, age, body mass index, diabe-
tes, dyslipidemia, the stage of risk and smoking showed 
no significant trend. Similar results were reported by Gay 
et al. in the Chinese population [27]. The frequency of the 
homozygous mutant 677TT was statistically higher in 
patients with a history of heart disease in the family. This 
finding might help in the genetic counseling. However, 
other family histories showed a comparable distribution 
among the different genotypes of MTHFR C677T. How-
ever, Alghasham et  al. in Saudi Arabia showed no asso-
ciation of the patient’s family history and MTHFR C677T 
genotypes [28]. We found that, the frequency of the wild 
type homozygous CC was higher in controls than in 
patients and subjects carriers of 677TT were associated 
with an increased risk hypertension (OR 5.4, p = 0.008). 
In addition, in the recessive model, we noticed that 
patients with the 677TT genotype were significantly asso-
ciated with the risk of hypertension (OR 5.3, p = 0.005). 
Markan et al. reported similar observations in the Indian 
population [29]. Yan et al. also reported in a meta-analy-
sis a strong association of MTHFR C677T with the risk 
of hypertension among Asians, Caucasians and Chinese 
subjects [30]. Similar findings were obtained in the popu-
lation of Turkey [7]. Many authors have reported that 
the MTHFR C677T polymorphism has been found to be 
an independent factor of hypertension in different eth-
nic groups [31–33] as well as of severe diastolic hyper-
tension in pregnant women [34]. These above studies 
showed that the MTHFR C677T polymorphism is asso-
ciated with a high level of homocysteine. This study did 
not assess the level of homocysteine. However, a previ-
ous study conducted by Bennouar et al. in 2007 showed 
that the 677TT genotype was statistically higher in sub-
jects with coronary artery disease and was found to be 
associated with hyperhomocysteinemia in Morocco [35]. 
In this study, it should be noted some limitations. First, 
our sample size was small, which reduces the statistical 
power. Secondly, the absence of the determination of 
homocysteine in patients and controls failed to establish 
the correlation between the variants of MTHFR and the 
values of homocysteine. Thirdly, hypertension is a com-
plex disease; other candidate genes may contribute to 
the susceptibility of hypertension. With respect to these 
limitations, the results of this study should be interpreted 
with caution. Other studies of large sample, overcoming 
the current limitations might be interesting in the under-
standing of the role of candidate genes in the susceptibil-
ity of hypertension in our population.
Conclusion
We have looked the influence of MTHFR C677T and 
the risk of hypertension in a sample of the Moroccan 
population. We have shown that, the homozygous mutant 
677TT was significantly associated with the risk of hyper-
tension. Additionally, the recessive model showed the 
same trend. Considering the size of our sample, further 
studies will be needed to confirm our findings.
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